US Measles Cases 2026: Alarming 4,410, Third Death
US measles cases 2026 reach 4,410 per the CDC, with a third death reported. Pennsylvania counts 1,286 cases and five deaths. What the numbers mean.
Emvistegrast Phase 2 Success: Bold Oral Colitis Data
Emvistegrast Phase 2 results: Gilead’s oral pill met the SWIFT primary endpoint in ulcerative colitis, 66% vs 37% on placebo. Not yet approved.
PerQseal Elite Gets FDA Nod: Bold Large-Bore Closure Win
PerQseal Elite, Haemonetics’ bioabsorbable patch for large-bore arterial closure, gets an FDA decision. What the data show and what is unknown.
AstraZeneca Oracle AI Pact: Bold Trial Plan, Key Limits
AstraZeneca Oracle AI agreement targets clinical-trial recruitment and safety monitoring, starting with hypertension in Abu Dhabi.
Lycia Therapeutics IPO: $938M Valuation Target, Big Risks
Lycia Therapeutics IPO targets up to a $937.7 million valuation with 14.7 million shares at $16 to $18. Terms, use of proceeds and risks.
RAP-219 Bipolar Mania Trial: Positive Result, Key Caveats
RAP-219 bipolar mania trial meets its primary endpoint in Phase 2: a 3.1-point gain over placebo, plus safety data and limits.
Paras Healthcare IPO Opens October 21: Price Band, Risks
Paras Healthcare IPO opens 21 October: a Rs 1,450 crore issue, Rs 660-693 price band and the hospital business explained.
BPL Medical Technologies Medec Acquisition: Global Bet
BPL Medical Technologies Medec acquisition: a majority stake adds three patents and distributors in 30+ countries. What is and is not disclosed.
ICMR Medical Device Development Initiative: Bold Plan
ICMR medical device development initiative: seven centres, including five IITs, get up to Rs 15 crore each. What is reported and what is not.
Fortis Hospital Kitchen Licence Suspended: Hygiene Alarm
Fortis Hospital kitchen licence suspended: Maharashtra FDA acts against the Mulund kitchen operator. What was found and what Fortis said.